SYNCHRONIZE-1 Phase III Readout on Survodutide
Key Takeaways
- Boehringer Ingelheim said survodutide met both co-primary endpoints in SYNCHRONIZE-1 under the efficacy and treatment-regimen estimands.
- A key secondary endpoint showed a statistically significant reduction in waist circumference versus placebo at 76 weeks, alongside company-reported weight loss.
- Gastrointestinal events were expected and generally mild to moderate and temporary, discontinuations were more frequent during dose escalation, and ADA 2026 data plus additional readouts are expected in 2026.
SYNCHRONIZE-1 was a Phase III, double-blind, placebo-controlled, 76-week efficacy and safety trial in 725 adults with obesity or overweight without type 2 diabetes. Participants received weekly injections of survodutide or placebo, and the company identified survodutide as BI 456906, a glucagon/GLP-1 receptor dual agonist. The co-primary endpoints were percentage change in body weight from baseline to week 76 and achievement of at least 5% weight reduction. Boehringer Ingelheim said both endpoints were assessed using the efficacy estimand and the treatment-regimen estimand.
For mean weight change, Boehringer Ingelheim reported sustained weight loss of up to 16.6% after 76 weeks on the efficacy estimand versus 3.2% with placebo, with nominal p<0.0001. The company also highlighted an absolute reduction of up to 39.2 lb, or 17.8 kg, from baseline. Initial analysis suggested the reduction was driven predominantly by fat loss, with lean mass accounting for only a small share. A key secondary endpoint also showed a statistically significant reduction in waist circumference versus placebo after 76 weeks. Together, these findings summarized the main efficacy results beyond the responder endpoint.
Safety details were limited in the topline update. Gastrointestinal events occurred, and discontinuations were more frequent during dose escalation. The company said those events were generally mild to moderate and temporary. It also reported no new safety concerns beyond what is expected for the GLP-1 class. Survodutide remains investigational and is not approved.
Boehringer Ingelheim said full SYNCHRONIZE-1 data will be presented at the American Diabetes Association’s 2026 Scientific Sessions in June. The company also said additional trial results are expected during 2026. It described SYNCHRONIZE-1 as part of a broader global Phase III obesity program for survodutide. That program includes studies in other key subpopulations, according to the company. Upcoming presentations and additional readouts are the next reported milestones through 2026.
Frequently Asked Questions
What's the latest on GLP-1 receptor agonists for obesity and weight management?
SYNCHRONIZE-1, a Phase III, double-blind, placebo-controlled, 76-week trial in 725 adults with obesity or overweight without type 2 diabetes, tested once-weekly survodutide (BI 456906) — a glucagon/GLP-1 receptor dual agonist — versus placebo. Boehringer Ingelheim's topline release reported sustained mean weight loss of up to 16.6% on the efficacy estimand versus 3.2% with placebo (nominal p<0.0001), an absolute reduction of up to 39.2 lb (17.8 kg) from baseline, and up to 85.1% of survodutide participants achieving ≥5% weight reduction at week 76 versus 38.8% on placebo. A key secondary endpoint also showed a statistically significant reduction in waist circumference versus placebo at 76 weeks.
Where can I find CME on tirzepatide and dual incretin agonists?
The Advances in Obesity Management Learning Center on ReachMD aggregates accredited education on dual incretin agonism (tirzepatide as GIP/GLP-1; survodutide as glucagon/GLP-1) and on the broader obesity pharmacotherapy landscape: Advances in Obesity Management. Specialty endocrinology episodes are at Endocrinology CME. As Phase III readouts accumulate for survodutide (SYNCHRONIZE-1), tirzepatide (SURMOUNT series, SURPASS-CVOT), and emerging multi-agonists, the CME hub is updated with new modules; both are free after a no-cost ReachMD registration.
What's new in obesity medicine for primary care?
For primary care, the headline shift is that obesity pharmacotherapy now spans selective GLP-1 receptor agonists (semaglutide 2.4 mg, 7.2 mg in STEP UP), dual incretin agonists (tirzepatide; survodutide in SYNCHRONIZE-1), and the first oral non-peptide GLP-1 RA (orforglipron, FDA-approved under CNPV; maintenance therapy after injectables in ATTAIN-MAINTAIN). SYNCHRONIZE-1 adds survodutide to the differentiated-mechanism shelf. Primary care implications include rising patient interest in glucagon/GLP-1 dual agonism, the need to recognize the GI adverse event profile shared across the class, and growing options for first-line therapy in adults with obesity or overweight with weight-related comorbidities without diabetes.
What were the safety findings for survodutide in SYNCHRONIZE-1?
Boehringer Ingelheim's topline release described safety as broadly consistent with the GLP-1 class. Gastrointestinal events occurred and were generally mild to moderate and temporary. Discontinuations were more frequent during dose escalation. The company reported no new safety concerns beyond what is expected for the GLP-1 class. Full safety details — including discontinuation rates, adjudicated events, and lab signals — are scheduled for presentation at the American Diabetes Association 2026 Scientific Sessions in June, and the peer-reviewed publication is awaited. Survodutide remains investigational and is not FDA-approved.
How does survodutide compare with tirzepatide and semaglutide, and what are the key uncertainties?
SYNCHRONIZE-1 was a placebo-controlled trial, not a head-to-head comparison with tirzepatide or semaglutide. Cross-trial comparisons are limited by differences in dose escalation, baseline characteristics, and endpoint definitions; the headline 16.6% mean weight loss at 76 weeks is within the range reported for high-dose tirzepatide and exceeds historical results for semaglutide 2.4 mg, but a direct comparison is not yet available. Other uncertainties include long-term durability beyond 76 weeks, comparative cardiovascular outcomes, performance in subpopulations (older adults, ethnic subgroups, patients with type 2 diabetes), and the role of glucagon receptor agonism in differentiating efficacy and safety from selective GLP-1 RAs and GIP/GLP-1 dual agonists.